Good afternoon, and welcome to INNOVATE Corp.'s third quarter 2022 earnings conference call. All participants will be in a listen-only mode today. After prepared remarks and presentation, there will be a question-and-answer session. Please note this event is being recorded. I would now like to turn the conference call over to Anthony Rozmus with investor relations. Please go ahead. Good afternoon. Thank you for being with us to review INNOVATE's third quarter 2022 earnings results. We're joined today by Avram Glazer, Chairman of INNOVATE, Wayne Barr, Jr., CEO of INNOVATE, and Michael Sena, INNOVATE's chief financial officer. We have posted our earnings release and our slide presentation on our website at innovatecorp.com. We will begin our call with prepared remarks to be followed by a Q&A session. This call is also being simulcast and will be archived on our website. During this call, management may make certain statements and assumptions which are not historical facts, will be forward-looking, and are being made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks, assumptions, and uncertainties and are subject to certain assumptions and risk factors that could cause Innovate's actual results to differ materially from these forward-looking statements. Risk factors that could cause these differences are more fully disclosed in the cautionary statement that is included in our earnings release and the slide presentation and further detailed in our 10-K and other filings with the SEC. In addition, the forward-looking statements included in this conference call are only made as of the date of this call and as stated in our SEC reports. Innovate disclaims any intent or obligation to update or revise these forward-looking statements except as expressly required by law. Management will also refer to certain non-GAAP financial measures such as adjusted EBITDA. We believe that these measures provide useful supplemental data that, while not a substitute for GAAP measures, allow for greater transparency in the review of our financial and operational performance. At this point, it's my pleasure to turn things over to Avram Glazer. Good afternoon. Innovate achieved another quarter of strong financial results. We grew both our top and bottom line once again, which we have done every quarter this year. Consolidated revenue for the third quarter grew 7.1%, and adjusted EBITDA increased 14.7% over the prior year period. It's encouraging to see the sustained growth in the first nine months of 2022 in the midst of a weaker macro backdrop. Infrastructure headlined the results as that business continues to benefit from a strong construction market and delivered revenue and adjusted growth while also expanding margins. The backlog also grew in the quarter, which continues to provide visibility and a pathway to future revenue and cash flows. In life sciences, revenue has grown sequentially each consecutive quarter in 2022. That said, we are navigating challenges in China related to lockdowns, which has negatively impacted our results in the quarter. Despite the slowdown, MediBeacon and R2 continue to make incremental progress. In the third quarter, R2 had 20% revenue growth as compared to the second quarter and has now shipped 215 units globally. MediBeacon patient enrollment is 85% complete with its U.S. pivotal study and is expected to finish the study by year-end. MediBeacon targets its final FDA submission in the first half of 2023. In broadcasting, we continue our focus on leveraging the scale of Spectrum Station group distribution platform and take advantage of the opportunities by optimizing operations. I'd like to again highlight the resiliency of each of our businesses. We have delivered growth on the top and bottom lines throughout 2022 despite the challenging operating environment. I'm confident our teams in each of the businesses will continue to execute our strategy and drive long-term growth and unlock future value. With that, I'm pleased to turn the call over to Wayne Barr, Jr. Thanks, Avram, and thank you all for joining us today. Across our three businesses, I'm proud of the results we delivered for the third quarter. By continuing our company-wide focus on operations, we achieved year-over-year growth on a consolidated basis. I will now share some third quarter highlights for each of our operating segments. At DBM Global, Banker Steel has been a part of DBM for more than a year now, and it's clear that the expected benefits from that acquisition continue to unfold. The expanded scale and footprint has allowed DBM to capture a larger scale of the revenue opportunities associated with increased demand for large construction projects. Revenue and adjusted EBITDA grew 7.8% and 13.1%, respectively. As we have mentioned on previous calls, we are now starting to see the improved margins as the pandemic-related jobs have started to roll off and jobs sold in the second half of 2021 are ramping up. Adjusted EBITDA margin expanded 30 basis points year-over-year and 120 basis points sequentially. DBM continues to generate robust revenue while also growing its backlog. Sales into backlog were $843.8 million for the quarter, outpacing revenue recognized during that quarter once again. As you can see, Rustin and the team have not seen a slowdown in the market at this point and continue to take advantage of the current environment. The heightened backlog continues to give the business great visibility into 2023 and beyond. Turning now to life sciences. R2 has now shipped 215 Glacial devices, and the monthly number of patients treated has continued to grow. Additionally, R2 implemented a new subscription sales program designed to fuel growth as it continues to explore various clinical initiatives for the Glacial products, including psoriasis and other inflammatory conditions. While these are still early days, there appears to be a much greater end market and application for this novel technology. At MediBeacon, the U.S. pivotal study has continued to progress well and now has enrolled 85% of its subjects. Both MediBeacon and R2 have been active on the trade show circuit, appearing at various events as speakers. MediBeacon is presenting at the American Society of Nephrology Kidney Week in Orlando, and R2 will be presenting at two upcoming investor conferences, Cantor Fitzgerald's Medical and Aesthetic Dermatology, Ophthalmology, and MedTech Conference, and Jefferies Virtual Private MedTech Summit. Finally, at Spectrum, the continued challenges in the operating environment had an adverse impact on our results. During the quarter, we made the strategic decision to exit Azteca America. Azteca America experienced sustained declining viewership and high cost for content and post-production services, making it a very challenging environment for success. By exiting Azteca, we will remove a significant portion of variable costs from the Spectrum business. This is part of our strategy to optimize operations, decrease costs, and improve overall results at Spectrum over the long run. With the pending availability of prime channels on the Azteca stations, we have been approached by dozens of programmers looking for carriage. In fact, we have already executed or will be shortly executing contracts to fill over one-third of the channels previously occupied by Azteca. While overall revenue will decrease as a result of the closure, we will be replacing unprofitable revenues with profitable revenues, which will have a positive impact on broadcast cash flow and EBITDA. We are starting to see a reversal of the trend in the overall softness in the television advertising market this year, particularly direct response, which has slowed the growth of multicast networks. Revenue prospects for new network launches on our platform look promising as we move into 2023. In September, we successfully completed the upgrade to ATSC 3.0 of two of our Fort Wayne, Indiana, stations. This upgrade is in conjunction with the FCC experimental special temporary authority granted to conduct a mobile wireless trial with our LPTV spectrum. The trial will likely commence in early December. While there is still much work to do, we are excited to be at the forefront of exploring the opportunities and expanded capabilities of ATSC 3.0 in conjunction with our current OTA linear broadcasting use. During the quarter, we completed the build-out of a new station for licensed WKOB-LD in New York City, which was relocated as a result of displacement from the incentive auction. The new site for the station is One World Trade Center, providing a far-ranging, robust signal to the New York City market. Outside of our operating segments, certain regulatory administrative items have delayed the closing of the HMN sale. We are still working through the mechanics of selling the 19% ownership in HMN and have encountered administrative regulatory hurdles that we expect to be short-term in nature. Lastly, we recognize the level the stock is trading at currently and are aware of the New York Stock Exchange listing regulations. We have been working with the stock exchange and have been very cooperative and are working diligently on a plan to get the stock back over $1 over the next six months. Overall, we are pleased with the continued resiliency demonstrated by our three businesses this past quarter and year to date, despite challenging operating environments. Looking ahead, we remain focused on executing our strategy across infrastructure, life sciences, and spectrum and believe we are poised for growth in each of our operating segments. With that, I'll turn it over to Mike for a review of our financials and capital structure. Thanks, Wayne. Consolidated total revenue for the third quarter of 2022 was $423 million, an increase of 7.1% compared to $394.8 million in the prior year period. The increase is driven by our infrastructure segment, led by the contribution from Banker Steel, and increases in infrastructure market demand. Net loss attributable to common and participating preferred stockholders for the third quarter of 2022 was $6.6 million or 9 cents per share, compared to a net loss of $213 million or $2.75 per share in the prior year period. As a reminder, we recognized a $200.3 million dollar loss on the sale of the insurance segment in the third quarter of the prior year. Total adjusted EBITDA, which excludes discontinued operations, was $16.4 million in the third quarter of 2022, an increase from an adjusted EBITDA of $14.3 million in the prior year period. The increase was primarily driven by the Infrastructure segment and our investment in HMN, which was partially offset by a decrease at our Spectrum, non-operating corporate, and Life Sciences segments. At Infrastructure, revenue increased 7.8% to $412.7 million from $383 million in the prior year quarter. As discussed earlier, this increase is driven by Banker Steel as they are in full swing into the work at 270 Park Avenue. They also saw an increase in DBM's commercial structural, steel fabrication, and erection business as they work through some of the larger wins from 2021, including Intuit Dome. The increase was offset in part by the industrial maintenance and repair and construction modeling and detail businesses due to unrepeated large projects completed in 2021 and early 2022. Infrastructure adjusted EBITDA for the third quarter of 2022 increased to $27.6 million from $24.4 million in the prior year period. The increase was largely driven by revenue increases previously described, combined with an improvement in margin as projects sold in the first half of 2021 and earlier are working their way through the system. Projects subsequently sold in the second half of 2021 are now beginning to ramp up. The improvements in profit and margin were partially offset by increased selling, general, and administrative costs to support growth in the business, as well as lower contributions from the industrial maintenance and repair and construction modeling and detail businesses. We have previously discussed that projects typically take 12-18 months to work off through backlog, and we are happy to see the jobs sold in the peak of the pandemic roll off and newer jobs begin to ramp up. As of September 2022, reported backlog was $1.9 billion, up from $1.6 billion as of December 31, 2021. Adjusted backlog, which takes into consideration awarded but not yet signed contracts, was $2.2 billion, compared to $1.9 billion at the end of December 2021. As Wayne mentioned, we are happy to continue to see a robust market, as evidenced by over $840 million of jobs sold into backlog this quarter. We expect to work through over $1.5 billion of this backlog in the next twelve months, giving great visibility into the next couple of years. DBM Global ended the quarter with $247.5 million of debt, which is an increase of $58.9 million from year-end, driven by working capital movements, which were at a low at year-end, combined with top-line business growth. At Life Sciences, the slight increase in adjusted EBITDA losses were driven primarily by a decrease in gross margin at R2, which was primarily due to a change in product mix and an increase in equity method losses recorded from our investment in MediBeacon as they work through their final pivotal trial. We discussed last quarter the $10 million bridge commitment made by Lancer Capital to R2, which will be repaid by year-end or a successful equity raise. The $10 million commitment was fully funded during the third quarter. At Spectrum, revenue decreased $1.1 million, or 10.8%, to $9.1 million as a result of lower advertising revenue at the Azteca business as a result of a decreased footprint and declines in paid programming. Spectrum delivered adjusted EBITDA of $3.3 million in the third quarter compared to adjusted EBITDA of $1.8 million in the prior year quarter. The decrease was the result of a decline in network or Azteca revenues, combined with increased content and service costs related to the network business, along with, to a lesser extent, higher station costs as a result of the new build stations. This was partially offset by a decrease in salaries and benefits and legal expenses. As you know, our Spectrum debt comes due at the end of the month, and consistent with prior years, we plan to extend the debt maturity and are far along in our discussions with our existing lenders. Non-operating corporate adjusted EBITDA losses were $5 million for the third quarter of 2022, up from the third quarter of 2021 by $1.2 million, driven mostly by accrued severance related to the former chief legal officer, as well as increased legal expenses. At the end of the third quarter, the company had $25.8 million of cash and cash equivalents, compared to $45.5 million as of December 31, 2021. On a stand-alone basis, as of September 3, 2022, the corporate segment had cash and cash equivalents of $5.1 million compared to $22 million at the end of 2021. As of September 30, 2022, Innovate had total principal outstanding in indebtedness of $711.5 million, up from $80.7 million to $630.8 million at the end of 2021, driven primarily by Infrastructure's increase in its line of credit as a result of working capital movements, Corporate's utilization of the remaining credit line as discussed in the previous quarter, and R2's borrowing from Lancer Capital. Our DBM cash continues to be partially tied up in working capital. We expect to meet our upcoming obligations mainly through the DBM tax share agreement, along with cash on hand while we work through longer-term solutions to support the working capital needs and dividend distributions during this time of tremendous growth we are experiencing with DBM. We navigated the first nine months of 2022 well and look to close out the year strong. For each of our operating segments, our focus is on what is within our control. We recognize that each businesses face unique challenges, but we are proud of all of our employees and the results that their hard work has generated to date. With that, operator, we'd now like to open up the call for questions. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. Our first question will come from Brian Charles with R. W. Pressprich Please go ahead. Hi, good afternoon. Congratulations on the quarter. The infrastructure certainly turned around or not turned around, but certainly continued to improve like you had guided earlier. I guess I have a quick question about the broadcast business. Leaving Azteca America, looks like your revenue will come down, but you say the net effect on EBITDA should be relatively positive. Do you have any color on that, what kind of scale that could be in terms of the positive EBITDA effect? Yeah. We really haven't said, you know, and don't give any projections. If you kind of take a look historically at how the Station Group operates, you do have a fixed cost operation there. It really is a matter of putting additional revenue on those stations. As we exit the Azteca business, that does free up some of the stations that we had previously been using to broadcast Azteca. We are in the process of monetizing those new stations. It should be at a higher margin than what we've been experiencing by operating on the Azteca network there, and we would expect that trend would continue as we use up the channels that were previously dedicated to Azteca and eliminate all of the variable costs associated with the operation of Azteca. It's fair to assume that the revenue you're losing with Azteca right now should be replaced as you sign up other I would just slightly. the stations. Bit of a modification. Yeah. I mean, I would expect overall revenue to come down in the broadcasting segment. But I would expect that we will replace what would be intercompany revenue between the network for Azteca business and the broadcasting business. In essence, we will add revenue to the remaining business, but eliminate all the costs associated with the network business. Okay. Are there exit costs or restructuring costs associated with exiting Azteca? Not anything material. You know, as you know, there weren't an awful lot of fixed assets there. We're working through a couple of the obligations that we will be terminating, but there are no significant exit costs or wind down costs associated with exiting this business. Okay. Fair enough. One other thing. I don't know if you can talk about third quarter, but if you ended the quarter with about $5.1 million of cash at the corporate level, can I ask how you paid the coupon on the 8.5% notes in August? Well, we borrowed on the revolver up at the corporate level, and that's how we made the payment, which we had talked about previously. Okay. That was a drawdown during the third quarter. Okay. Yeah. No, all right. Fair enough. Yeah. The interest payment's due August 1 and February 1. Yeah. It's a semi-annual interest payment, that's due in August. We borrowed on the line towards the end of July. Did mention that last quarter, and that's how we made the coupon payment. Okay, thanks. Then finally, and I'll get back in queue. The residual marine services put with HMN, I know you all have been talking about that, and you made a comment about just some regulatory headwinds right now. Do you still expect those to be resolved though in the fourth quarter? In the fourth quarter? Yeah, you know, we think that the headwinds that we're facing primarily arising out of regulatory issues that are being experienced in China by the purchaser, as well as the continued Chinese lockdowns have delayed consummating the sale of that. We are constantly iterating with the counterparties there and trying to get this done as quickly as possible. You know, we're hopeful that it will be concluded by the end of the year. Okay, that's good. Thanks. That's all I got for now. Very good. Thank you, Brian. Our next question will come from Bryant Riley with B. Riley Financial. Please go ahead. Hey, guys. Hey, Wayne. Thanks for taking the call. I mean, we've been in this forever, like, you know, maybe three years before you and, you know, saw the rights offering and have seen the whole process and had great deal of respect for your path. It's obviously been a challenging investment for all. I guess I wanted to take a second and understand the bigger picture and kind of the bigger thesis as we looked at it and make sure that we're not thinking about it incorrectly and then just get any potential thoughts you might have, recognizing you're an insider. You know, as I look at the balance sheet. Simply, you know, net debt of $709 million. I appreciate that some of that's gonna go up and down based on working capital needs. You've got a subsidiary that's doing roughly $100 million of EBITDA. I believe it's a lot of free cash flow when it's not dealing with supply chain issues and other things that I would imagine it's dealing with now. I'd love to hear some thoughts on that. It could trade at a decent multiple. I'm not suggesting you're selling it, but you know, if it traded at 7x your EBITDA multiple, you would have all of your debt gone, again, simplistically. That leaves you with Spectrum and Life Sciences. Spectrum, I don't know the value of that biz. We've never been able to really fully underwrite that, so no clue. Life Sciences, for a long time there's been some really big numbers thrown around, not from you guys, but just around, about the potential of that business. That to me represents kind of the call option, if you believe that, you know, the infrastructure business is worth 7x and you'll have no debt and you'll have these assets. Wayne, remind me what you still. I heard you guys talking about it, but I don't fully understand what you have at Global Marine. I think it's $30 million or something. That's been. There's 80 million shares or something like that. If those Life Sciences businesses are worth $500 million plus the J&J call option, it can be meaningful. That's been the really simplistic way we've thought about it, unfortunately. I mean, it hasn't worked. The other side that I had never really thought about and contemplated was the corporation not having enough money to pay the interest, which I, you know, obviously you had to borrow from the revolver. What I would love to know, number one, is what I just laid out, does that make any sense to you? Does just, I'd love to hear your thoughts on what I laid out. Two, what happens around, you know, is this corporate interest payment of $13 million and I guess you have overhead, how does that, you know, is that. That's every six months, so I guess you can make. Help us understand and get comfort with that because if we believe the thesis that there's so much incremental value, I'm sure you'll figure it out and what the options would be. Then on the Lancer debt to Life Sciences, I'd love to understand the equity component because I think a big part of the thesis if you're an investor with Lancer, is that we're gonna be treated, you know, right by insiders. I'm certain we are. The rights offering is always fair. A lot to unpack there. Would love to hear your thoughts. Sure, Bryant. Unfortunately, Avi was not able to stay on the phone for the balance of the call. He had a prior obligation. You know, obviously we are, you know, we're in touch every day. At the risk of not speaking for him, but trying to answer some of your questions from management's perspective, you know, your interpretation and your summary of the business is fairly accurate. As you said, you've been in the name for a while. I think the recent things that we've been doing since the new board was seated over the course of the last two years was trying to sharpen the focus at the company. We've done that by maintaining and continuing to operate the three operating segments that, you know, quite honestly, this board, which is led by Avi, believe represent very good value. DBM, obviously a much more mature company than both Broadcasting and the two entities at Spectrum. As a consequence, the holding company leans on the more mature company from a cash flow perspective, and we'll continue to do that. They've had a tremendous run at DBM. That team is exceptional at operating their business and selling new business, and we would expect that would continue to be the case. You know, I think we've seen a little bit of liquidity constraint, which has been driven by just the levels at which the company's able to sell new business. We're working through a variety of different ways to help solve that liquidity issue. But if you take a look at the backlog in particular, the way this business operates, it gives you very good visibility into, you know, the next 18-24 months of operations from DBM. From that perspective, I think you have a fairly good, you can have a fairly good idea as to what this business is worth. You know, I think the board at Innovate truly appreciates the value that DBM represents, not only currently, but also going forward, in the next 24 months or so. The other two companies, as we've indicated, you know, the other two operating segments need longer runways to realize the value. All three of the companies that are divided between those two operating segments, I believe are working very effectively to try to realize that value. We're supporting them in whatever manner we can. I think the focus of Station Group at Broadcasting is going to help tell the story and create value there. Both Pansend and R2 are performing in the manner that, you know, we're very happy with at the holding company, and we would expect them to continue to move forward. The MediBeacon pivotal is going very well and we would hope that as they move towards applying for FDA approval, that the successes that MediBeacon has experience will continue. I think, you know, those are kind of the approaches that this board took when it decided to divest of Beyond6 and Continental. I think the focus on these three operating segments right now, and the results kinda speak for themselves this quarter, was an accurate way to move this company forward in light of some of the constraints that it has, including the debt service, which you point out. We've been, I think, diligent in our planning and have put in place a path forward to satisfy the liquidity needs at the parent, including the debt service on the bonds. I think, you know, we've demonstrated with the last interest payment and some of the additional steps that we're taking that we're going to be able to execute on that path, and we're going to be able to satisfy our liquidity needs going forward. This board and management is looking at, you know, basically every opportunity that comes our way to continue to generate value here. The companies, the performances is good at each of the companies. We do have the liquidity constraints that we're working through, but again, we have a path forward to solving them, and I'm very confident that we're going to be able to do that. Having invested in companies like infrastructure business, you know, I know those can be high utilization of cash, especially in a growth mode. Can you tell me what you think on a normalized basis, what the free cash flow conversion is on a $100 million EBITDA run rate? What would you expect free cash flow to be, forgetting the working capital swings and one project might be pushed out, but in general, how do you think of free cash flow conversion? I think about it in context of one, you know, they're running call it historically $15 million-$20 million of CapEx with the Banker Steel business on an annual basis. The debt load is call it $7 million-$8 million. Then, you know, outside of that and, you know, the debt amortization that they have, which we have put on one of our slides, the rest is kind of free cash flow outside of their working capital needs. Right. Okay. Then in terms of your NOL, I know that there's been a poison pill put in place to prevent impairing that. Can you just give us the status of that? Sure. The pill expires in February or in March, I believe. End of February, beginning of March. Yeah. It was re-upped for a shorter period than the annual re-up the last time the stockholders approved it. We were able to add to the NOL this quarter through the consolidation of the first half of 2021 results on consolidated tax return with Continental. I think we added about $63 million to the NOL. You know, we continue to think that it's a valuable asset and the pill being in place, I think is the right thing to do. The calculation of the change of control is as you'd know, pretty convoluted by virtue of the IRS regulations that have put that in place. The board did an analysis that got us comfortable that there'd be purchases that would roll off by in the February, March timeframe that would enable us to you know, eliminate the pill and not be at risk for having the limitation under Section 382 by virtue of a change of control. I would just say that, you know, to think about the history of the changes in ownership, you know, the Section 382 change of control is on a three year rolling period. Most of our changes all happened in 2020, or at least a big piece of the shift was created when you had firstly Rochdale come in in January, Lancer Capital in May, and then of course in November, we had the rights offering. So those are the biggest causes of the shift. You know, in 2023, those will begin to roll off, you know, at those timeframes, basically. Got it. Three follow-ups, and I'll go. Sorry. One comment. First of all, I think a company like this, the perfect way if you have a shortage to deal with this is through a rights offering to the extent that you have equity holders that believe in the valuation. I know you've done that before. I think the worst way to deal with it would be an outright equity offering where, you know, you kind of picked and choose who participated. I just wanna point out that B. Riley Financial, if there was a need because of a gap, because of working capital infrastructure, would be a big proponent of not diluting shareholders who wanted to re-up. You know, when you have this, and I'm not saying you're gonna need it, but I just wanted to point that out, so that's one. Two is, I forget the Global Marine outstanding potential payable and where that goes. I thought it was $35 million or something. Do you know what I'm talking about? We still hold a 19% interest in that equity investment. That is what we are working on trying to Close and transact. It's at the same valuation that we had when we sold the original 30%. That's a $285 million equity value. 19% is $54 million. There is a local tax, call it roughly 10%. We have some transaction-related fees attached to that deal. You know, we don't own 100% of the entity that owns that interest, so we have about a little over 70% interest there. That we expect to get about $32 million. Got it. That's what you were talking about, you were hoping to get by the end of the year. Right. You know, one concern you would have if you were, you know, an outside shareholder is that in times of trouble, you know, some of the lendings to to other subsidiaries might be onerous. I don't think that's the case here, but just to relieve any potential concern, can you talk about the Lancer debt into the life sciences business and what that looked like? Senior secured piece of paper with no equity component. Awesome. That's great. All right. Thank you. Thanks, Brian. Appreciate your support. Again, if you have a question, please press star then one to join the queue. Our next question will come from Nitin Sacheti with Papyrus Capital. Please go ahead. Hey, guys. Looking at the breakdown of the backlog in the queue, it looks like government is still pretty low at $13 million. Just curious, when we think about sort of the Infrastructure Bill, the CHIPS Act, the IRA, when you think that comes through, unless that's sort of classified elsewhere in backlog, and just generally how you're thinking about sort of the, I guess, the distribution of funds to the states and, you know, when we think that'll hit the DBM business. The Infrastructure Act? Yeah, Yeah, Infrastructure Act, CHIPS, all of them. I mean, we really haven't seen, as far as I know, any contribution to the sales that these guys have been making out of DBM that could be attributed to any kind of governmental funds being made available for infrastructure, you know. If it has happened, it hasn't been flagged to us. Okay, thanks. Any sense of timing as to when that might hit backlog then? Not from my perspective, you know. I mean, right now, I think you're seeing tremendous growth in DBM's backlog. They sold $143 million into backlog. The market is quite robust from what we've seen, and we haven't seen it slow down. We have not seen anything from the infrastructure bill come into the market, as Wayne mentioned, and that's my understanding also. I think to the extent there are projects that come into backlog, that's down the road. I think right now the DBM team is taking advantage of what's in the market, and we see that in what's happening with the backlog, which of course has given us really good visibility into the next two years. Okay. Thank you, guys. That's helpful. Great. Thanks, Nitin. This will conclude our question and answer session. I'd like to turn the call back over to Wayne Barr, Jr. for any closing remarks. Thanks, Joe. We appreciate everyone's participation on this earnings call today, and I hope everybody has a nice evening. Thank you. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect your lines.